百时美施贵宝拥有70亿美金来收购其他公司。
The firm also has some $7 billion in cash with which to pursue other acquisitions.
随后引发的财政混乱导致了百时美施贵宝的总裁下台。
The resulting financial chaos led to the ousting of Bristol-Myers's boss.
于是，猜测辉瑞的收购目标成了当前最热门的话题：百时美施贵宝？
Thus, speculation has become a takeover target Pfizer today's hottest topic: Bristol-Myers Squibb?
英克隆将提留西妥昔单抗在美收入的39%，而百时美施贵宝将获得其余部分。
ImClone will keep 39 per cent of US revenues from Erbitux, with Bristol-Myers Squibb taking the rest.
在9月7日收盘前，百时美施贵宝股票价格上涨3美分，至每股26.61美元。
Bristol-Myers shares rose 3 cents to close earlier at $26.61.
一些常用药包括非专利药二甲双胍，它是百时美施贵宝公司的产品，商品名叫格华止。
Some common medications include metformin, which is available generically and also known by the Bristol-Myers Squibb brand name Glucophage.
排在食品巨人阿彻·丹尼尔斯·米德兰和药业巨兽百时美施贵宝的之前，并紧随在沃尔玛、通用汽车和石油巨头科氏工业集团的后面。
It ranks ahead of food giant Archer Daniels Midland, pharmaceutical behemoth Bristol Myers Squibb and just behind in ranking of Wal-mart, General Motors and oil magnate, Koch Industries.
因为百时美施贵宝仍将拥有ImClone公司的抗癌拳头产品Erbitux(爱必妥)北美市场的销售收益，这将使收购方无法获得该公司现有的大部分收益。
Because BMS will keep the North American marketing rights for Erbitux, ImClone's blockbuster cancer drug, much of the firm's current revenue will not go to the buyer.
纽约股市方面，高盛公司把百时美施贵宝公司(Bristol - Myers squibb)的评级从“中性”调高到“买入”后，这家制药商的股价上涨5.4%。
Bristol-Myers Squibb Co. jumped 5.4 percent in New York after Goldman Sachs Group Inc. raised its rating on the drugmaker to "buy" from "neutral."
药物在筛选中的优化以及在早期开发中的策略徐文祺博士， 高级主管， 百时美-施贵宝药业（美国）
Optimization in Drug Candidate Selection and Strategy in Early Drug Development, Wen Chyi Shyu, Ph. D. , Bristol-Myers Squibb, NJ, USA.
药物在筛选中的优化以及在早期开发中的策略徐文祺博士， 高级主管， 百时美-施贵宝药业（美国）
Optimization in Drug Candidate Selection and Strategy in Early Drug Development, Wen Chyi Shyu, Ph. D. , Bristol-Myers Squibb, NJ, USA.
应用推荐